Lastly, Dr. West discussed federal policies relating to the industry of regenerative medicine. He announced an open letter to President-Elect Obama signed by 22 scientists and economists (including 19 Nobel laureates), urging the new Administration to make regenerative medicine, specifically, the cure of human disease, a national priority, similar in scope to the Kennedy Administration's commitment to land a man on the moon within that decade. The text of the letter to President-Elect Obama is available online at www.biotimeinc.com.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.
BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend, PentaLyte, HetaCool, EmbryomicsTM, ESpyTM, and ESpanTM, are trademarks of BioTime, Inc.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential op
Copyright©2008 Vocus, Inc.
All rights reserved